Related Experiment Video
Updated: Jun 1, 2026
Bioluminescent Bacterial Imaging In Vivo
Published on: November 4, 2012
From Bacteria to Breakthroughs: Design and Evaluation of Gallocin-Based Peptide for Colorectal Cancer Therapeutic
Batoul Kavyani1, Fereshteh Saffari2, Ali Afgar3
1Medical Mycology and Bacteriology Research Center, Kerman University of Medical Sciences, Kerman, Iran.
Abstract:
Developing targeted cancer therapies with high selectivity, low toxicity, and cost-effectiveness remains a major challenge in modern medicine. This study aimed to design a Gallocin-derived anticancer peptide (ACP) targeting the epidermal growth factor receptor (EGFR) using an integrated bioinformatics and experimental approach. Gallocin, a bacteriocin from Streptococcus gallolyticus, was selected for its unique four α-helix structure and anticancer motifs, making it a promising candidate for ACP in initial in silico analysis. The Gallocin-derived ACPs were predicted using web-based tools. Molecular docking studies assessed the binding affinity of ACPs to EGFR, and molecular dynamics simulations analyzed the stability of the Galcn-1-EGFR complex. The absorption, distribution, metabolism, excretion, and toxicity (ADMET) analysis evaluated pharmacokinetic properties. Docking revealed that Galcn-1 had a high binding affinity for EGFR, forming stable hydrogen bonds. Molecular dynamics simulations confirmed complex stability. Experimental validation showed that Galcn-1 exhibited an IC₅₀ of 16 µg/ml in HT-29 cells. Galcn-1 downregulated EGFR and PI3K expression, induced apoptosis via both extrinsic (CAS-8) and intrinsic (CAS-9) pathways, increased ROS production, and caused cell cycle arrest in the S-phase. Pharmacokinetic evaluations indicated improved metabolism and lower toxicity, along with decreased permeability and a shorter half-life. Future optimization through bioengineering, such as peptide conjugation and chemical modifications (PEGylation), use of a synthetic staple, and development of drug delivery systems, will enhance stability, protect the peptide from proteolytic degradation, extend its half-life and binding affinity, and improve permeability and function, positioning Galcn-1 for further preclinical and clinical development.
Insights
A novel Gallocin-derived anticancer peptide, Galcn-1, shows high binding affinity to epidermal growth factor receptor (EGFR) and effectively inhibits cancer cell growth, offering a promising targeted therapy candidate.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Targeted cancer therapies with high selectivity, low toxicity, and cost-effectiveness are crucial.
- Epidermal growth factor receptor (EGFR) is a key target in cancer therapy.
- Gallocin, a bacteriocin, possesses anticancer motifs suitable for peptide development.
Purpose of the Study:
- To design and validate a Gallocin-derived anticancer peptide (ACP) targeting EGFR.
- To evaluate the binding affinity, stability, and anticancer efficacy of the designed ACP.
- To assess the pharmacokinetic properties and potential toxicity of the ACP.
Main Methods:
- Bioinformatics tools for ACP design and prediction.
- Molecular docking and dynamics simulations for binding and stability analysis.
- In vitro experimental validation including IC50, apoptosis, cell cycle, and ROS assays.
- Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) analysis.
Main Results:
- Galcn-1 demonstrated high binding affinity to EGFR with stable complex formation.
- Experimental validation showed Galcn-1 has an IC50 of 16 µg/ml in HT-29 cells.
- Galcn-1 induced apoptosis, increased ROS, caused S-phase arrest, and downregulated EGFR/PI3K.
- ADMET analysis indicated improved metabolism, lower toxicity, and reduced permeability.
Conclusions:
- Galcn-1 is a potent EGFR-targeting anticancer peptide with promising therapeutic potential.
- Further optimization via bioengineering can enhance Galcn-1's stability, half-life, and efficacy.
- Galcn-1 is well-positioned for preclinical and clinical development as a targeted cancer therapy.